Heart Failure Reviews最新文献

Correction to: Worsening heart failure: progress, pitfalls, and perspectives. 更正：恶化的心力衰竭：进展、陷阱和前景。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-28 DOI: 10.1007/s10741-025-10507-0

Cândida Fonseca, Rui Baptista, Fátima Franco, Brenda Moura, Joana Pimenta, Pedro Moraes Sarmento, José Silva Cardoso, Dulce Brito

引用次数: 0

Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management. 肝硬化心肌病：病理生理学、诊断和管理的综合见解。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-12 DOI: 10.1007/s10741-025-10500-7

Andrew Ndakotsu, Tagbo Charles Nduka, Simran Agrawal, Edinen Asuka

{"title":"Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.","authors":"Andrew Ndakotsu, Tagbo Charles Nduka, Simran Agrawal, Edinen Asuka","doi":"10.1007/s10741-025-10500-7","DOIUrl":"10.1007/s10741-025-10500-7","url":null,"abstract":"Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction linked to chronic liver disease, primarily characterized by impaired cardiac response to stress, despite normal baseline function. It presents with both systolic and diastolic dysfunction, along with electrophysiological changes such as QT interval prolongation. CCM is driven by a combination of systemic inflammation, nitric oxide-induced vasodilation, and neurohormonal dysregulation, leading to myocardial impairment and abnormal vascular responses. Clinically, CCM often remains asymptomatic at rest, but patients may experience exercise intolerance or heart failure during stress. Diagnosis includes echocardiographic evaluation, biomarker analysis (NT-proBNP, troponins), and electrocardiography for detecting electrophysiologic abnormalities. Management is complicated by cirrhosis, limiting the use of conventional heart failure treatments, with liver transplantation being the most definitive intervention in severe cases. Early detection of CCM is vital, particularly for patients undergoing liver transplantation or major surgery, where cardiac complications can increase mortality. Further research is necessary to refine diagnostic criteria and treatment strategies.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"739-748"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy. 新兴的，新的基因调节治疗转甲状腺素淀粉样心肌病。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-08 DOI: 10.1007/s10741-025-10502-5

Song Peng Ang, Jia Ee Chia, Debabrata Mukherjee

{"title":"Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy.","authors":"Song Peng Ang, Jia Ee Chia, Debabrata Mukherjee","doi":"10.1007/s10741-025-10502-5","DOIUrl":"10.1007/s10741-025-10502-5","url":null,"abstract":"Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the pathological deposition of misfolded transthyretin (TTR) protein in the myocardium, leading to restrictive cardiomyopathy and heart failure. While TTR stabilizers such as tafamidis and acoramidis are the only FDA-approved treatments, novel gene-modulating therapies are emerging as transformative approaches. Small interfering RNA (siRNA) and antisense oligonucleotide (ASO) therapies effectively reduce TTR production and have demonstrated promising clinical outcomes, though their use in cardiac amyloidosis remains investigational. CRISPR-Cas9 therapies represent a paradigm shift, offering a potential one-time treatment by permanently silencing the TTR gene. Recent clinical trials have shown significant TTR reduction and stabilization of disease biomarkers, although long-term safety and efficacy require further evaluation. Despite the lack of direct comparisons among these modalities, their emergence highlights a promising future for ATTR-CM management. This review discusses the pathogenesis of ATTR-CM, mechanisms of novel gene-modulating therapies, clinical evidence, challenges, and the future outlook for advancing treatment options.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"759-770"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renal denervation in the setting of heart failure. 心衰情况下的肾去神经。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-01-29 DOI: 10.1007/s10741-025-10489-z

Franziska Koppe-Schmeißer, Karl Fengler, Karl-Patrik Kresoja, Philipp Lurz, Karl-Philipp Rommel

引用次数: 0

Noninvasive biometric monitoring technologies for patients with heart failure. 针对心力衰竭患者的无创生物识别监测技术。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2024-10-22 DOI: 10.1007/s10741-024-10441-7

Jose Arriola-Montenegro, Pornthira Mutirangura, Hassan Akram, Adamantios Tsangaris, Despoina Koukousaki, Michael Tschida, Joel Money, Marinos Kosmopoulos, Mikako Harata, Andrew Hughes, Andras Toth, Tamas Alexy

{"title":"Noninvasive biometric monitoring technologies for patients with heart failure.","authors":"Jose Arriola-Montenegro, Pornthira Mutirangura, Hassan Akram, Adamantios Tsangaris, Despoina Koukousaki, Michael Tschida, Joel Money, Marinos Kosmopoulos, Mikako Harata, Andrew Hughes, Andras Toth, Tamas Alexy","doi":"10.1007/s10741-024-10441-7","DOIUrl":"10.1007/s10741-024-10441-7","url":null,"abstract":"Heart failure remains one of the leading causes of mortality and hospitalizations in the US that not only impacts quality of life but also poses a significant public health burden. The majority of affected patients are admitted with signs and symptoms of congestion. Despite the initial enthusiasm, traditional remote monitoring strategies focusing primarily on weight gain failed to improve clinical outcomes. Implantable pulmonary artery pressure sensors provide earlier and actionable data, but most patients would favor forgoing an invasive procedure in favor of an alternative, non-invasive monitoring platform. Several devices utilizing different combinations of multiparameter monitoring to reliably detect congestion have recently been developed and are undergoing testing in the clinical setting. Combining these sensors with the power of artificial intelligence and machine learning has the potential to revolutionize remote patient monitoring and early congestion detection and to facilitate timely interventions by the care team to prevent hospitalization. This manuscript provides an objective review of novel, noninvasive, multiparameter remote monitoring platforms that may be tailored to individual heart failure phenotypes, aiming to improve quality of life and survival.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"657-672"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leptin and heart failure: the chicken or the egg? 瘦素和心力衰竭：是先有鸡还是先有蛋？

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-17 DOI: 10.1007/s10741-025-10501-6

Nikolaos Theodorakis, Maria Nikolaou

{"title":"Leptin and heart failure: the chicken or the egg?","authors":"Nikolaos Theodorakis, Maria Nikolaou","doi":"10.1007/s10741-025-10501-6","DOIUrl":"10.1007/s10741-025-10501-6","url":null,"abstract":"Leptin plays a dual role in heart failure (HF), acting as either a primary driver or a secondary phenomenon depending on the HF subtype. In HF with preserved ejection fraction (HFpEF), chronic hyperleptinemia is a primary mediator of disease initiation and progression, closely linked to obesity and metabolic dysfunction. Elevated leptin levels promote systemic inflammation, sympathetic nervous system activation, arterial stiffness, myocardial hypertrophy, fibrosis, and sodium retention, culminating in diastolic dysfunction and elevated ventricular filling pressures. Conversely, in HF with reduced ejection fraction (HFrEF), elevated leptin levels arise as a secondary response to myocardial dysfunction, systemic inflammation, and tissue hypoperfusion. Here, leptin exacerbates cardiac dysfunction by amplifying neurohormonal activation, inflammation, and cardiac remodeling. Understanding these distinct roles has potential therapeutic implications. In HFpEF, interventions such as weight loss, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and mineralocorticoid receptor antagonists can improve symptoms and prognosis, partly by mitigating chronic hyperleptinemia. Furthermore, leptin-specific therapies should be investigated in clinical trials as potential approach in managing cardiometabolic HFpEF. In HFrEF, management focuses on guideline-directed therapies targeting neurohormonal activation-the key mechanism driving disease progression. However, future research should explore whether modulating leptin signaling could provide additional benefits translated in hard clinical endpoints. By framing leptin as the initiator (\"chicken\") in HFpEF and a consequence (\"egg\") in HFrEF, this manuscript highlights the need for individualized, integrated treatment strategies. Addressing both metabolic and cardiovascular components could potentially further improve patient outcomes and quality of life.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"749-757"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Left atrial shunting devices: why, what, how, and… when? 左心房分流装置：为什么，什么，怎么做，什么时候？

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-01-25 DOI: 10.1007/s10741-025-10485-3

Leila Anna De Lorenzo, Claudia Baratto, Davide Sala, Giovanni Battista Perego, Sergio Caravita

引用次数: 0

Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives. 心力衰竭的心脏和大脑相互作用：病理生理机制和临床观点。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-18 DOI: 10.1007/s10741-025-10505-2

Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis

{"title":"Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives.","authors":"Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis","doi":"10.1007/s10741-025-10505-2","DOIUrl":"10.1007/s10741-025-10505-2","url":null,"abstract":"Heart failure (HF) is a complex and debilitating syndrome that affects millions of people worldwide. In addition to the syndrome-related functional limitations, such as exercise intolerance and dyspnea, patients frequently suffer from various comorbidities. Neuropsychiatric conditions, including autonomic dysfunction, cognitive impairment, and depression, are important albeit underrecognized comorbidities in HF. Autonomic dysfunction, which is expressed as sympathetic predominance and decreased parasympathetic tone, is a key contributor to HF progression. Depression and cognitive impairment are highly prevalent in HF patients, affecting adherence to medical treatment and increasing morbidity and mortality risk. Stress cardiomyopathy, a usually reversible form of left ventricular dysfunction triggered by emotional or physical stress, is another clinical manifestation of the interplay between the heart and the brain. Early recognition and management of these comorbidities in HF patients are crucial for improving outcomes. This narrative review provides an overview of the pathophysiological mechanisms linking HF and brain disorders and discusses clinical perspectives of heart-brain interactions in the context of HF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"791-800"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the lymphatic system. 利用淋巴系统

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2024-10-15 DOI: 10.1007/s10741-024-10449-z

Barbara Ponikowska, Marat Fudim, Gracjan Iwanek, Robert Zymliński, Jan Biegus

{"title":"Harnessing the lymphatic system.","authors":"Barbara Ponikowska, Marat Fudim, Gracjan Iwanek, Robert Zymliński, Jan Biegus","doi":"10.1007/s10741-024-10449-z","DOIUrl":"10.1007/s10741-024-10449-z","url":null,"abstract":"Heart failure (HF) is a growing concern, with significant implications for mortality, morbidity, and economic sustainability. Traditionally viewed primarily as a hemodynamic disorder, recent insights have redefined HF as a complex systemic syndrome, emphasizing the importance of understanding its multifaceted pathophysiology. Fluid overload and congestion are central features of HF, often leading to clinical deterioration and hospital admissions, with the role of the lymphatic system previously largely overlooked, partly due to diagnostic challenges and visualization difficulties. With the advancement of those techniques, pathophysiological changes occurring in the lymphatic system during HF, such as enlargement of the thoracic duct and the increased lymphatic flow, are now becoming apparent. This emerging research has begun to uncover the interplay between lymphatic dysfunction and HF, suggesting novel therapeutic targets. Advances in molecular biology, such as targeting vascular endothelial growth factor and promoting lymphangiogenesis, hold promise for improving lymphatic function and mitigating HF complications. This article provides a comprehensive overview of the evolving landscape of lymphatic system-targeted therapies for HF. It explores various intervention levels, from mechanical lymphatic decongestion to pharmaceutical interactions and lymphatic micro-circulation, offering insights into future directions and potential clinical implications for HF management.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"673-683"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF). 心力衰竭伴射血分数保留（HFpEF）的运动不耐受机制。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-13 DOI: 10.1007/s10741-025-10504-3

Brandon Pecchia, Roy Samuel, Vacha Shah, Emily Newman, Gregory T Gibson

{"title":"Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF).","authors":"Brandon Pecchia, Roy Samuel, Vacha Shah, Emily Newman, Gregory T Gibson","doi":"10.1007/s10741-025-10504-3","DOIUrl":"10.1007/s10741-025-10504-3","url":null,"abstract":"Exercise intolerance is a well-established symptom of heart failure with preserved ejection fraction (HFpEF) and is associated with impaired quality of life and worse clinical outcomes. Historically attributed to diastolic dysfunction of the left ventricle, exercise intolerance in HFpEF is now known to result not only from diastolic dysfunction, but also from impairments in left ventricular systolic function, left atrial pathology, right ventricular dysfunction, and valvular disease. Disorders of heart rate and rhythm such as chronotropic incompetence and atrial fibrillation have also been implicated in exercise intolerance in this population. Pathologic changes to extra-cardiac organ systems including the respiratory, vascular, hormonal, and skeletal muscle systems are also thought to play a role in exercise impairment. Finally, comorbidities such as obesity, inflammation, and anemia are common and likely contributory in many cases. The role of each of these factors is discussed in this review of exercise intolerance in patients with HFpEF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"777-789"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0